Abstract：Lung cancer is a common malignant tumor with high morbidity and mortality. Many patients die of distant metastases, especially to the brain. Due to the existence of blood-brain barrier and blood-tumor barrier, drug therapy is not effective. Many studies have shown that imbalanced expression of molecules plays an important role in the progression of malignant tumors. Epidermal growth factor receptor, non-coding RNA, cell adhesion molecules and others are reported to participate in regulating the process of brain metastases from non-small cell lung cancer, they also have high clinical translational value in diagnosis, treatment and evaluation of patient prognosis. This paper summarizes the recent progress of brain metastasis in non-small cell lung cancer, hoping to provide ideas and clues for future research.
马力 朱娅 王朝霞. 非小细胞肺癌脑转移研究进展[J]. 中国医药导报, 2023, 20(3): 37-40,54.
MA Li ZHU Ya WANG Zhaoxia. Research advances in brain metastasis of non-small cell lung cancer. 中国医药导报, 2023, 20(3): 37-40,54.
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2022 [J]. CA Cancer J Clin，2022，72（1）：7-33.
[3] Reck M，Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer [J]. N Engl J Med，2017，377（9）：849-861.
[4] Waqar SN，Samson PP，Robinson CG，et al. Non-small-cell Lung Cancer With Brain Metastasis at Presentation [J]. Clin Lung Cancer，2018，19（4）：e373-e379.
[5] Bui N，Woodward B，Johnson A，et al. Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer [J]. Curr Treat Options Oncol，2016，17（5）：25.
[6] Brower JV，Robins HI. Erlotinib for the treatment of brain metastases in non-small cell lung cancer [J]. Expert Opin Pharmacother，2016，17（7）：1013-1021.
[7] Zhang J，Jin J，Ai Y，et al. Differentiating the pathological subtypes of primary lung cancer for patients with brain metastases based on radiomics features from brain CT images [J]. Eur Radiol，2021，31（2）：1022-1028.
[8] Gupta GP，Massague J. Cancer metastasis：building a framework [J]. Cell，2006，127（4）：679-695.
[9] Srinivasan ES，Tan AC，Anders CK，et al. Salting the Soil：Targeting the Microenvironment of Brain Metastases [J]. Mol Cancer Ther，2021，20（3）：455-466.
[10] Tobar LE，Farnsworth RH，Stacker SA. Brain Vascular Microenvironments in Cancer Metastasis [J]. Biomolecules，2022，12（3）：401.
[11] Gan DX，Wang YB，He MY，et al. Lung Cancer Cells-Controlled Dkk-1 Production in Brain Metastatic Cascade Drive Microglia to Acquire a Pro-tumorigenic Phenotype [J]. Front Cell Dev Biol，2020，8：591405.
[12] Huang X，Hussain B，Chang J. Peripheral inflammation and blood-brain barrier disruption： effects and mechanisms [J]. CNS Neurosci Ther，2021，27（1）：36-47.
[13] Sprowls SA，Arsiwala TA，Bumgarner JR，et al. Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption [J]. Trends Cancer，2019，5（8）：495-505.
[14] Steeg PS. The blood-tumour barrier in cancer biology and therapy [J]. Nat Rev Clin Oncol，2021，18（11）：696-714.
[15] Shah R，Lester JF. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer： A Clash of the Generations [J]. Clin Lung Cancer，2020，21（3）：e216-e228.
[16] Doebele RC，Lu X，Sumey C，et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer [J]. Cancer，2012，118（18）：4502- 4511.
[17] Wang BX，Ou W，Mao XY，et al. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC [J]. Clin Neurol Neurosurg，2017，160：96-100.
[18] Fujita Y，Kinoshita M，Ozaki T，et al. The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases [J]. Neurooncol Adv，2020，2（1）：a64.
[19] Ge M，Zhuang Y，Zhou X，et al. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases [J]. J Neurooncol，2017，135（2）：413- 418.
[20] Colclough N，Chen K，Johnstrom P，et al. Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs [J]. Clin Cancer Res，2021，27（1）：189-201.
[21] Li H，Tong F，Meng R，et al. E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer [J]. Cell Mol Life Sci，2021，78（6）：2877- 2891.
[22] Kim M，Suh CH，Lee SM，et al. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation： Cumulative Incidence and Risk Factor Analysis [J]. AJR Am J Roentgenol，2021，217（5）：1184-1193.
[23] Yang B，Lee H，Um SW，et al. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations [J]. Lung Cancer，2019，129：28-34.
[24] Chen S，Hua X，Jia J，et al. Risk factors for brain metastases in patients with non-small cell lung cancer：a meta-analysis of 43 studies [J]. Ann Palliat Med，2021，10（4）：3657- 3672.
[25] 刘洋，贾永森，秦丽娟.microRNA-155在缺氧肺癌脑转移中的作用[J].四川大学学报（医学版），2019，50（6）：835-839.
[26] Jin Y，Kang Y，Peng X，et al. Irradiation-Induced Activated Microglia Affect Brain Metastatic Colonization of NSCLC Cells via miR-9/CDH1 Axis [J]. Onco Targets Ther，2021， 14：1911-1922.
[27] Wang H，Deng Q，Lv Z，et al. N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1 [J]. Mol Cancer，2019，18（1）：181.
[28] Wei L，Wang G，Yang C，et al. MicroRNA-550a-3-5p controls the brain metastasis of lung cancer by directly targeting YAP1 [J]. Cancer Cell Int，2021，21（1）：491.
[29] Wei C，Zhang R，Cai Q，et al. MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer [J]. Aging （Albany NY），2019，11（17）：6734-6761.
[30] Jiang W，Hou L，Wei J，et al. Hsa-miR-217 Inhibits the Proliferation，Migration，and Invasion in Non-small Cell Lung Cancer Cells Via Targeting SIRT1 and P53/KAI1 Signaling [J]. Balkan Med J，2020，37（1）：208-214.
[31] Wu D，Deng S，Li L，et al. TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non- small cell lung cancer brain metastasis [J]. Cell Death Dis，2021，12（8）：721.
[32] Jiang C，Zhao H，Yang B，et al. lnc-REG3G-3-1/miR- 215-3p Promotes Brain Metastasis of Lung Adenocarcinoma by Regulating Leptin and SLC2A5 [J]. Front Oncol，2020，10：1344.
[33] Munsterberg J，Loreth D，Brylka L，et al. ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium [J]. Neuro Oncol，2020，22（7）：955-966.
[34] Dai L，Zhao J，Yin J，et al. Cell adhesion molecule 2 （CADM2） promotes brain metastasis by inducing epithelial-mesenchymal transition（EMT）in human non-small cell lung cancer [J]. Ann Transl Med，2020，8（7）：465.
[35] Dai L，Li YH，Liang YY，et al. High expression of cell adhesion molecule 2 unfavorably impacts survival in non- small cell lung cancer patients with brain metastases [J]. J Thorac Dis，2021，13（4）：2437-2446.
[36] Aljohani HM，Aittaleb M，Furgason JM，et al. Genetic mutations associated with lung cancer metastasis to the brain [J]. Mutagenesis，2018，33（2）：137-145.
[37] Shih D，Nayyar N，Bihun I，et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma [J]. Nat Genet，2020，52（4）：371- 377.
[38] Li L，Liu Z，Han R，et al. Genetic Heterogeneity Between Paired Primary and Brain Metastases in Lung Adenocarcinoma [J]. Clin Med Insights Oncol，2020，14：2012324217.
[39] Zhang F，Ying L，Jin J，et al. GAP43，a novel metastasis promoter in non-small cell lung cancer[J]. J Transl Med，2018，16（1）：310.
[40] Wei C，Dong X，Lu H，et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/ MYC pathway [J]. J Exp Clin Cancer Res，2019，38（1）：95.
[41] Franchino F，Ruda R，Soffietti R. Mechanisms and Therapy for Cancer Metastasis to the Brain [J]. Front Oncol，2018， 8：161.
京公网安备 11010502046598号